Updates
Natco Pharma Limited is pleased to announce the approval of Doxorubicin Hydrochloride Liposome Injection by US FDA17-05-2017
17-05-2017
Natco launches generic cancer drug in India
Natco Pharma has launched generic version of pomalidomide capsules for treatment of blood cancer in the domestic market.Pomalidomide is sold by Celgene Inc in the US under the brand Pomalyst. The...10-05-2017
Updates
NATCO launches POMALID, first generic version of pomalidomide capsules, for treatment of a specific blood cancer, in INDIA10-05-2017
Natco Pharma launches hepatitis C drug Velpanat in India
Velpanat is generic version of Epclusa, which contains sofosbuvir (400 mg) & velpatasvir (100 mg)09-05-2017
Natco Pharma launches generic hepatitis C drug in India
Natco Pharma has launched generic sofosbuvir 400 mg/velpatasvir 100 mg tablets used for the treatment of chronic hepatitis C in India. The company has launched a generic version of sofosbuvir 400...08-05-2017
Updates
NATCO launches VELPANAT, generic version of Sofosbuvir 400 mg/Velpatasvir 100 mg fixed dose combination tablets in INDIA08-05-2017
31St March, 2017
Please find enclosed here with confirmation certificate as per Clause 7 (3) of Securities and Exchange Board of India ( Listing Obligations and Disclosure Requirements ) Regulations, 2015 for the period ended 31st March, 201717-04-2017
Certificate Under Clause 40 (10) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Half Year Ended 31St March, 2017
certificate under Clause 40 (10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the half year ended 31st March, 201717-04-2017
Multiple growth pills should keep Natco Pharma's revenue charts healthy
The Natco Pharma stock was up six per cent in two trading sessions on expectations of a strong March quarter performance and near-term triggers such as approval for generics of multiple sclerosis drug Copaxone. For the March quarter, while the pharma sector is expected to report single-digit revenue and flat net profit growth, Natco Pharma could witness a growth of 24 per cent in revenues and 117 per cent rise in its bottom line. The better performance is due to the launch of the generic version of influenza drug Tamiflu in December 2016 in the US. The drug, marketed by its US partner Alvogen, has sales of about $400 million. In addition to a strong March quarter performance, the next trigger is the approval for generics of Copaxone (40 mg strength) which has annual sales of $3.3 billion. The verdict on a patent case is due in May 2017 and a favourable outcome of this could mean a ~400-500-crore revenue opportunity, according to analysts. Natco, along with its US partner Mylan,...14-04-2017
Shareholding for the Period Ended March 31, 2017
Natco Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here07-04-2017